Agenda

Please note all sessions listed in Central Time. Agenda subject to change.

Thursday, April 15

Day 1

6:45 am

Registration Opens

7:15 am — 8:15 am

Breakfast & Non-CME/CE Bonus Presentation

8:15 am — 8:30 am

Exhibit & Poster Hall Opens

8:30 am — 8:40 am

Conference Welcome

8:40 am — 10:45 am

Session I: Advances in Myelodysplastic Syndromes and Precursor States

8:40 am — 8:45 am

Session Introduction

Richard M. Stone, MD

8:45 am — 9:05 am

We Should Start Therapy Prior to Transfusion Dependence in LR-MDS

Rami Komrokji, MD

9:05 am — 9:15 am

Audience Q&A

Richard M. Stone, MD
Rami Komrokji, MD

9:15 am — 9:35 am

What Can Spatial Transcriptomics Teach Us About Myelodysplastic Syndromes?

Susan DeWolf, MD

9:35 am — 9:45 am

Audience Q&A

Richard M. Stone, MD
Susan DeWolf, MD

9:45 am — 10:05 am

When To Include a Workup For Germline Predisposition States Like Short Telomere Syndrome or Other Germline States

Christopher R. Reilly, MD

10:05 am — 10:15 am

Audience Q&A

Richard M. Stone, MD
Christopher R. Reilly, MD

10:15 am — 10:35 am

Targeting the Inflammasome to Treat MDS

Alan List, MD

10:35 am — 10:45 am

Audience Q&A

Richard M. Stone, MD
Alan List, MD

10:45 am — 11:15 am

Break: Visit Exhibit & Poster Hall

11:15 am — 11:55 am

Stump the Experts: MDS & AML

MDS Expert - Pinkal Desai, MD
MDS Fellow - Kian J. Rahbari, MD
AML Expert - Eunice S. Wang, MD

11:55 am — 1:30 pm

Session II: Pre-Clinical Translational Research

11:55 am — 12:00 pm

Session Introduction

Ravindra Majeti, MD, PhD

12:00 pm — 12:20 pm

Modeling the Malignant Niche: 3D Systems and Spatial Biology in AM

Iannis Aifantis, MD

12:20 pm — 12:30 pm

Audience Q&A

Ravindra Majeti, MD, PhD
Iannis Aifantis, MD

12:30 pm — 12:50 pm

No More Marrows? Mapping Circulating Stem Cells in AML

Liran I. Shlush, MD, PhD

12:50 pm — 1:00 pm

Audience Q&A

Ravindra Majeti, MD, PhD
Liran I. Shlush, MD, PhD

1:00 pm — 1:20 pm

What’s the Leukemia Forecast: Predicting Relapse After Transplant

Peter van Galen, PhD

1:20 pm — 1:30 pm

Audience Q&A

Ravindra Majeti, MD, PhD
Peter van Galen, PhD

1:30 pm — 2:30 pm

Lunch & Non-CME/CE Bonus Presentation

2:30 pm — 2:45 pm

Refreshment Break: Visit Exhibit & Poster Hall

2:45 pm — 3:50 pm

Session III: Novel Strategies in ALL

2:45 pm — 2:50 pm

Session Introduction

Wendy Stock, MD

2:50 pm — 3:10 pm

Pearls and Pitfalls: Challenges and Opportunities of Blinatumomab

Marlise R. Luskin, MD

3:10 pm — 3:20 pm

Audience Q&A

Wendy Stock, MD
Marlise R. Luskin, MD

3:20 pm — 3:40 pm

Pick Your Poison: Pivekimab vs Tagraxofusp for BPDCN

Rita Assi, MD

3:40 pm — 3:50 pm

Audience Q&A

Wendy Stock, MD
Rita Assi, MD

3:50 pm — 4:05 pm

Break: Visit Exhibit & Poster Hall

4:05 pm — 5:40 pm

Session IV: Multidisciplinary Care

4:05 pm — 4:10 pm

Session Introduction

Tiffany Tanaka, MD

4:10 pm — 4:30 pm

From Snouts to Souls: How Palliative Pigs Caultivate Resilence, Joy and Purpose in Leukemia Care

Krista Dobbie, MD

4:30 pm — 4:40 pm

Audience Q&A

Tiffany Tanaka, MD
Krista Dobbie, MD

4:40 pm — 5:00 pm

Going PRO: Why (the right) Patient Outcomes Are Crucial for AML Studies

Catherine Lai, MD, MPH

5:00 pm — 5:10 pm

Audience Q&A

Catherine Lai, MD, MPH

5:10 pm — 5:30 pm

Best Practices for Evaluation of Elderly AML Patients for BMT Eligibility

Reena V. Jayani-Kosarzycki, MD, MSCI

5:30 pm — 5:40 pm

Audience Q&A

Tiffany Tanaka, MD
Reena V. Jayani-Kosarzycki, MD, MSCI

5:40 pm — 6:40 pm

Refreshments & Non-CME/CE Bonus Presentation

6:40 pm — 7:40 pm

Welcome Reception

7:40 pm

Day One Adjourns

Friday, April 16

Day 2

7:00 am

Registration Opens

7:15 am — 8:15 am

Breakfast & Non-CME/CE Bonus Presentation

8:15 am — 8:30 am

Exhibit & Poster Hall Opens

8:30 am — 8:35 am

Welcome Back

8:35 am — 10:10 am

Session V: Acute Myeloid Leukemia

8:35 am — 8:40 am

Session Introduction

Joshua F. Zeidner, MD

8:40 am — 9:00 am

The Significance of Mutation Location in AML Prognostication

Andrew Kent, MD, PhD

9:00 am — 9:10 am

Audience Q&A

Joshua F. Zeidner, MD
Andrew Kent, MD, PhD

9:10 am — 9:30 am

Why Do We Need So Many Menin Inhibitors? Meaningful Clinical Differences (if any) Between Drugs

Ghayas Issa, MD

9:30 am — 9:40 am

Audience Q&A

Joshua F. Zeidner, MD
Ghayas Issa, MD

9:40 am — 10:00 am

Dealing with Abundance: Should We Preferentially Target FLT3 When There Are Multiple Targetable Mutations (NPM1, IDH1/2)?

Jessica Altman, MD

10:00 am — 10:10 am

Audience Q&A

Joshua F. Zeidner, MD
Jessica Altman, MD

10:15 am — 11:15 am

Refreshments & Non-CME/CE Bonus Presentation

11:15 am — 11:45 am

Break: Visit Exhibit & Poster Hall

11:45 am — 12:45 pm

Session VI: Ernest Beutler Memorial Lecture

11:45 am — 11:55 pm

Introduction

Eytan M. Stein, MD

11:55 am — 12:35 pm

Ernest Beutler Memorial Lecture

Jacob M. Rowe, MD

12:35 pm — 12:45 pm

Audience Q&A

Eytan M. Stein, MD
Jacob M. Rowe, MD

12:45 pm — 1:45 pm

Lunch & Non-CME/CE Bonus Presentation

1:45 pm — 2:00 pm

Refreshment Break: Visit Exhibit & Poster Hall

2:00 pm — 3:45 pm

Session VII: Bone Marrow Transplant

2:00 pm — 2:05 pm

Session Introduction

Andrew Artz, MD, MS

2:05 pm — 2:25 pm

Don’t Be Late! Does the Timing of CAR-T Cell Therapy Influence Outcomes and Why?

Roni Shouval, MD, PhD

2:25 pm — 2:35 pm

Audience Q&A

Andrew Artz, MD, MS
Roni Shouval, MD, PhD

2:35 pm — 2:55 pm

Does GVHD Remain a Significant Issue in Modern Day Bone Marrow Transplants?

Javier Bolaños Meade, MD

2:55 pm — 3:05 pm

Audience Q&A

Andrew Artz, MD, MS
Javier Bolaños Meade, MD

3:15 pm — 3:35 pm

Should We Offer Allogeneic Stem Cell Transplants to Patients With Active Leukemia

Lori Muffly, MD, MS

3:35 pm — 3:45 pm

Audience Q&A

Andrew Artz, MD, MS
Lori Muffly, MD, MS

3:45 pm — 3:55 pm

Closing Remarks

3:55 pm

Conference Ends